HOME >> BIOLOGY >> NEWS
BioMed Central explodes Open Access myths

"A switch to Open Access would not negatively impact research funding," BioMed Central declared today. The Open Access publisher issued a strong rebuttal of arguments that have been submitted by opponents of Open Access to the ongoing UK House of Commons Select Committee inquiry into scientific publishing.

In (Mis)Leading Open Access Myths <http://www.biomedcentral.com/openaccess/inquiry/myths.pdf>, a statement released today, BioMed Central counters claims that Open Access publishing would cut into research funding, asserting:

"The vastly increased access to research that is delivered by Open Access will greatly increase the effectiveness of the research money that is spent."

The statement continues:

"Open Access publishers are leading the way in using web technology to reduce costs further, so the cost of. Open Access publishing to the scientific community will be significantly less than the cost of the system that it replaces."

Open Access publishing, which makes all original research articles freely available to anyone, has been a major focus of the Government inquiry.

Today's statement from BioMed Central responds to each of the major "anti-Open Access" arguments made during the course of the inquiry so far.

"We felt it was important, at this stage when many people are hearing about Open Access for the first time, to dispel some of these myths," says Jan Velterop, BioMed Central's Publisher.

Other myths dispelled in the document include: "transferring copyright to a publisher protects scientific integrity"; "UK researchers already have all the access they need"; "industry will benefit from Open Access at the expense of research institutes"; and "the public would be confused if they had access to medical research".

The BioMed Central statement appears on a new web page <

Contact: Grace Baynes
press@biomedcentral.com
44-20-7631-9988
BioMed Central
22-Mar-2004


Page: 1 2

Related biology news :

1. BioMed Central to consult funders and librarians over Open Access payment model
2. LA BioMed Medical/Research Briefs, July/August 2004
3. The Scientist and BioMed Central come together to publish high-impact magazine
4. BioMed Central is pleased to announce the publication of Sydney Brenners autobiography
5. BioMed Central to deposit e-journals with the British Library
6. BioMed Central to consider charging authors for paper submissions
7. Get Research on the move with BioMed Central
8. BioMed Central to launch at microbiology meeting
9. BioMed Central to free scientists and clinical researchers from copyright restrictions
10. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
11. Sediments in many Central Valley streams contain toxic levels of pyrethroid pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... Calif. (PRWEB) , ... November 13, 2019 , ... ... enrolled the first patients in an FDA approved clinical trial for stem cell ... of the formation of the company as a subsidiary of VetStem Biopharma. , In ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... Spend Optimizer that improves digital advertising performance up to 25% and reduces cost-per-click ... Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict best advertising outcomes ...
(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, ... played a key role in the award-winning study “Next Generation Sequencing for the ... The molecular diagnostic laboratory processed samples using Next Generation DNA Sequencing to examine ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... (PRWEB) , ... November 06, 2019 , ... Diversified ... whole pieces of fruits and vegetables per hour to improve processing. , The DTI ... of multiple tons per hour to increase juice yields by up to 50% and ...
(Date:11/2/2019)... ... 2019 , ... A clinical trial usually involves many different ... principal investigators, supply chain managers, manufacturers, IRT, CRAs and so on. Lack of ... data, potentially leading to patient risk. , By having a single source of ...
(Date:10/29/2019)... ... October 28, 2019 , ... CaroGen Corporation , a biotechnology ... , Professor Jack R Wands, MD, of Brown University , ... Professor Gil Mor, MD, PhD, of Wayne State University, formerly a professor at ...
(Date:10/22/2019)... (PRWEB) , ... October 22, 2019 , ... Catalent, a ... Supply Services and Drug Product Technologies Integration, will participate in a panel session titled ... (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019. , ...
Breaking Biology Technology:
Cached News: